About Careers Internship MedBlog Contact us
Medindia LOGIN REGISTER
Advertisement

Sandoz Receives Warning Letter for Manufacturing Violations At 2 Indian Sites From US FDA

by Shirley Johanna on October 28, 2015 at 5:31 PM
Font : A-A+

Sandoz Receives Warning Letter for Manufacturing Violations At 2 Indian Sites From US FDA

The US Food and Drug Administration (FDA) issued a warning letter to Sandoz, generic drug arm of Swiss giant Novartis for its two Indian sites at Kalwe and Turbhe on October 22.

The warning letter observations follow an agency inspection at both the sites in August 2014, the company said adding those are related to deficiencies in current good manufacturing practice (cGMP) for finished pharmaceuticals.

Advertisement

"The warning letter does not contain any new issues versus the 483 observations issued following the inspection in August 2014, which Sandoz has been addressing since then," it added.

"Sandoz will continue to work closely with the FDA to ensure all observations are resolved to the agency's full satisfaction. No supply disruptions are expected," it said.
Advertisement

Novartis ($NVS) acknowledged the issues on Tuesday in its earnings announcement, and Novartis, CEO, Joseph Jimenez touched on them during Q3 earnings discussion. He said the FDA issued the warning letter for the sites in Kalwe as well as one in Turbhe, a plant that Sandoz intends to close. Jimenez said he expected the warning letter would soon be published by the agency.

Jimenez gave no details about the agency's concerns but said that the company has been working on fixing the problems since the FDA raised red flags during an inspection in August 2014. The warning letter didn't include any additional concerns, Jimenez said. The company continues to ship products from the plants, and no supply issues have resulted from the episode.

Source: Medindia
Advertisement

Advertisement
News A-Z
A B C D E F G H I J K L M N O P Q R S T U V W X Y Z
What's New on Medindia
Know More About Mitochondria
Top 10 Foods for Decreasing DHT Production and Preventing Hair Fall
Alarming Cesarean Section Trends in India - Convenience or Compulsion of Corporate Healthcare
View all
News Archive
Date
Category
Advertisement
News Category

Medindia Newsletters Subscribe to our Free Newsletters!
Terms & Conditions and Privacy Policy.

Most Popular on Medindia

Calculate Ideal Weight for Infants Drug Interaction Checker Daily Calorie Requirements Blood Donation - Recipients Blood - Sugar Chart Post-Nasal Drip The Essence of Yoga Nutam (400mg) (Piracetam) Blood Pressure Calculator Drug Side Effects Calculator
This site uses cookies to deliver our services. By using our site, you acknowledge that you have read and understand our Cookie Policy, Privacy Policy, and our Terms of Use
×

Sandoz Receives Warning Letter for Manufacturing Violations At 2 Indian Sites From US FDA Personalised Printable Document (PDF)

Please complete this form and we'll send you a personalised information that is requested

You may use this for your own reference or forward it to your friends.

Please use the information prudently. If you are not a medical doctor please remember to consult your healthcare provider as this information is not a substitute for professional advice.

Name *

Email Address *

Country *

Areas of Interests